在ACS中通过LL-37免疫球蛋白G自身抗体免疫复合体调解的血小板激活的新途径
Paul C Dimayuga1, Kuang-Yuh Chyu1, Xiaoning Zhao1
1Oppenheimer Atherosclerosis Research Center, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
JACC. Basic to translational science
|August 22, 2024
概括
凯瑟利西丁抗微生物LL-37自身抗体与未来的心脏病发作有关. 在急性冠状动脉综合征中,降低的LL-37 IgG自身抗体与激活血小板的免疫复合体相关.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管医学 心血管医学
- 这是一种自身免疫力.
背景情况:
- 凯瑟利西丁抗微生物LL-37作为自身抗原,触发了自身免疫和自身炎症性疾病中的自身抗体的产生.
- LL-37自身抗体已与各种炎症状况有关,但它们在心血管疾病中的作用需要进一步研究.
研究的目的:
- 调查LL-37免疫球蛋白 (Ig) G自身抗体水平与动脉样硬化心血管疾病之间的关联.
- 为了确定LL-37 IgG水平是否预测未来心肌梗塞 (MI),并在急性冠状动脉综合征 (ACS) 中发生变化.
主要方法:
- 测量LL-37 IgG自身抗体水平在患有或没有冠状动脉的人,未来心脏病患者和ACS患者中.
- 对动脉样硬化疾病的冠状动脉分数的评估.
- 在ACS血中分析LL-37IgG-免疫复合体水平和血小板激活标志物 (CD62P+).
主要成果:
- LL-37 IgG水平与冠状动脉分数没有关联.
- 经历了未来心肌梗塞的患者的LL-37IgG水平在基线显著更高.
- 在ACS患者中,降低的LL-37 IgG与增加的LL-37 IgG免疫复合体有关,该复合体通过Fc玛受体2a促进了血小板激活.
结论:
- 较高的LL-37 IgG自身抗体可能作为未来心肌梗塞风险增加的生物标志物.
- 在急性冠状动脉综合征中,LL-37 IgG-免疫复合体有助于血小板激活,这表明在血栓事件中发挥了作用.
更多相关视频
11:18Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
Published on: April 2, 2013
15.7K
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
246
相关概念视频
01:22Formation of the Platelet Plug
5.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.3K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
6.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.5K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
501
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
501
01:16Clot Retraction and Fibrinolysis
4.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.9K
01:05Introduction to Hemostasis
6.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
6.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654